NanoSyrinx, the synthetic biology company developing ‘nanosyringes’ as a novel platform for targeted intracellular delivery ...

Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and ...

Ablynx has scored a major hit in phase 3 trials of caplacizumab, a new treatment for a rare blood clotting disorder. Shares in the Belgian biotech have soared on the news, rising 30% this morning ...

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...